LGVN News and Press, Longeveron Inc. From 08/14/23

2023-08-14 15:44:10 ET More on Longeveron Longeveron Inc. ( LGVN ) Q2 2023 Earnings Call Transcript Longeveron spikes on long-term survival data for heart disease candidate Longeveron spikes after FDA’s Fast Track Designation for lead candidate For...

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (...

2023-08-11 22:16:08 ET Longeveron Inc. (LGVN) Q2 2023 Earnings Conference Call August 11, 2023 08:00 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors, LLC Wa’el Hashad - Chief Executive Officer Nataliya Agafonova - Chief Medical ...

2023-08-11 10:57:47 ET Longeveron press release ( NASDAQ: LGVN ): Q2  Net loss was approximately $5.6 million for the three-month periods ended June 30, 2023 and 2022. Revenue of $0.2M (-60.0% Y/Y). For further details see: Longeveron reports Q2 results

ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS Top Line Results for CLEAR MIND Alzheimer’s disease Phase 2a Trial Anticipated by October 2023 Company Strengthens Leadership Team and Board of Directors with Distinguished ...

Company Activates Additional Study Location to Expedite Enrollment Completion Key Opinion Leader Webinar Highlighting the Potential for Lomecel-B™ in the Treatment of HLHS to be held Wednesday, August 16, 2023 at 10:00 AM ET MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Long...

(NewsDirect) By David Willey, Benzinga Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. Longeveron’s primary drug is Lomecel-B™, which is being developed as a potential thera...

MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its second quarter 2023 financia...

2023-07-20 08:17:54 ET Longeveron ( NASDAQ: LGVN ) has appointed Lisa Locklear as Executive Vice President and CFO, effective as of July 31, 2023. Ms. Locklear joins Longeveron from Avanir Pharmaceuticals, a subsidiary of Otsuka, where she served as Senior Vice P...

MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Lisa Locklear as Executive Vice P...